BVI Medical

BVI Medical, Inc. is a specialized manufacturer of innovative ophthalmic products, dedicated to enhancing surgical outcomes and improving patient care in eye care procedures across the globe. BVI Medical, Inc. is focused on developing a range of ophthalmic products.

Founded in 1932 in Waltham, US, the company has engaged in a strategic pivot towards advanced surgical solutions. In March 2025, BVI Medical secured USD 1 billion in a Growth funding round from TPG. The company operates with a single deal to its name, indicating a focused investment approach in the ophthalmic space. BVI Medical US specializes in manufacturing a comprehensive range of ophthalmic products, primarily targeting the surgical and therapeutic needs of eye care professionals.

The company's core offerings include innovative instruments for cataract and glaucoma surgeries, intraocular lenses, high-quality surgical fluids, and consumables designed for various ophthalmic procedures such as vitreoretinal, cornea, dry eye, lacrimal, oculoplasty, and refractive treatments. These products are developed to address specific clinical challenges faced by ophthalmologists, with a focus on enhancing surgical outcomes and improving patient care. BVI Medical's solutions are utilized by healthcare providers in over 90 countries, catering to hospitals, surgical centers, and eye care professionals who serve patients suffering from conditions including cataracts, refractive errors, glaucoma, and retinal diseases. BVI Medical generates revenue through direct sales of its ophthalmic products to healthcare institutions, including hospitals and surgical centers, as well as partnerships with distributors in international markets.

The transaction structure typically involves B2B sales, where healthcare providers place bulk orders for instruments and consumables essential for eye surgeries. Additionally, the company may offer value-added services to its clients, such as training for new products and surgical techniques. Major product lines include trademarked items such as IPure intraocular lenses, which are integral to cataract surgeries, and specialized surgical fluids used during procedures. The financial framework reflects a pricing strategy based on product types and volumes, allowing flexibility for bulk purchases while maintaining the quality standards that BVI Medical is known for.

In March 2025, TPG invested USD 1 billion in BVI Medical, Inc. to enhance its services and business development. The recent funding will support the design and launch of new products aimed at addressing emerging ophthalmic needs. Additionally, BVI Medical plans to expand into new markets, with a focus on strengthening its presence in Europe and Asia by the end of 2025.